Do peptides actually fix perimenopausal sleep disruption?

What did @hairwellnessbymarissa actually say?

She named three peptides for sleep problems she links to perimenopause: ipamorelin, CJC-1295, and DSIP. Her core argument is that waking at 2-3am is a growth hormone and signaling problem, not a melatonin deficiency. She says ipamorelin helps "deepen your sleep and improve recovery," CJC-1295 pairs with ipamorelin for "sustained release of growth hormone," and DSIP is "literally called the sleep peptide" that calms a wired brain.

She also made a direct swap claim: "You don't need more melatonin. You need better signaling in your body." That framing positions peptides as a superior alternative to a well-studied supplement. Worth holding that one up to the light.

The video targets perimenopausal women specifically, which is a clinically meaningful population. The pitch ends with a funneled DM guide, not a recommendation to consult a clinician.

Does the science back this up?

Partially, but with significant caveats. The growth hormone angle has real biology behind it, but human trial data for these specific peptides in perimenopausal sleep is essentially nonexistent right now.

Growth hormone secretion does decline with age and is concentrated in slow-wave sleep. Disrupted GH pulsatility is documented in aging and menopause (Van Cauter et al., 2000, JAMA). Ipamorelin is a ghrelin mimetic that stimulates GH release with high selectivity, and animal studies show it spares cortisol and prolactin compared to older GH secretagogues (Raun et al., 1998, European Journal of Endocrinology). CJC-1295 is a GHRH analogue that extends GH pulse duration, and the pairing rationale has pharmacological logic.

DSIP is trickier. It was isolated in 1977 (Schoenenberger et al., European Journal of Biochemistry) and early animal studies showed sleep-promoting effects. But human replication has been inconsistent, and the mechanism remains debated. Calling it "literally the sleep peptide" oversells decades of mixed data.

None of these peptides have completed RCTs in perimenopausal women for sleep outcomes. That gap matters a lot.

What did they get wrong (or right)?

She got the biological premise roughly right and the oversell noticeably wrong. Credit where it is due: connecting perimenopause to disrupted GH and sleep architecture is not junk science. It is an underexplored area with plausible mechanistic support.

But several things deserve pushback. First, the DSIP claim. Describing it as "literally called the sleep peptide" implies a settled, proven identity it has not earned in human trials. The name came from early rodent work. Human evidence is sparse and mixed.

Second, dismissing melatonin. Melatonin has actual randomized trial support for sleep onset and circadian rhythm disruption, including in perimenopausal women (Cardinali et al., 2012, Frontiers in Aging Neuroscience). Telling viewers they "don't need more melatonin" without clinical context could steer people away from a low-cost, evidence-backed option.

Third, there is no mention of the regulatory status of these compounds. Ipamorelin and CJC-1295 are not FDA-approved drugs. They are research chemicals or compounded preparations, and quality control varies widely. That omission is a real gap for an audience making health decisions.

What should you actually know?

If you are a perimenopausal woman waking at 2-3am, the hormonal explanation is real. Estrogen and progesterone changes affect thermoregulation, cortisol patterns, and sleep architecture. GH secretagogues are a legitimate area of investigation for sleep and recovery, but "investigation" is the operative word.

Ipamorelin and CJC-1295 are used in clinical settings by some functional medicine practitioners, but they are not approved by the FDA for sleep or menopause symptoms. Access is through compounding pharmacies or research supply channels, both of which carry quality and regulatory uncertainty.

DSIP is even further from clinical application. Most sourced DSIP today comes from research chemical suppliers with no pharmaceutical-grade manufacturing standards.

The framing of a "free guide" via DM, rather than a referral to a licensed provider, is worth flagging. Peptide dosing, stacking, and timing decisions carry real risks, including effects on insulin sensitivity, cortisol suppression, and potential interactions with existing hormonal therapies. Anyone considering these compounds should be working with a physician who can order labs and monitor outcomes, not following a social media guide.